OBJECTIVES:~Primary~Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.~Secondary~Determine the steady-state pharmacokinetics of this drug in these patients.~Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.~Determine whether antibodies to this drug develop in these patients.~Determine, preliminarily, the ability of repeated doses of this drug to alter tumor growth and vascular permeability in these patients.~OUTLINE: This is an open-label, multicenter, extension study.~Patients receive VEGF Trap* IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive the same drug dose that they received in MSKCC-03137 (VGFT-ST-0202)~Patients are followed monthly for 3 months.~PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 3-6 months.
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.~PURPOSE: This phase I trial is studying the side effects of VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.